Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of a new antithrombogenic continuous ultrafiltration system.

M Arakawa1, M Nagao, F Gejyo

  • 1Department of Medicine (II), Niigata University School of Medicine, Japan.

Artificial Organs
|June 1, 1991
PubMed
Summary

A novel antithrombogenic continuous ultrafiltration system (ACUS) using a polyacrylonitrile-polyethyleneoxide membrane and heparinized components demonstrated prolonged extracorporeal circulation times in animal models. This system shows excellent biocompatibility and sustained ultrafiltration for clinical use in acute renal failure patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic sclerosis in two second cousins: a case report.

Modern rheumatology·2014
Same author

Human parvovirus B19 infection mimicking systemic lupus erythematosus.

Modern rheumatology·2014
Same author

Effectiveness of omeprazole for the treatment of upper gastrointestinal lesions in rheumatoid arthritis patients.

Modern rheumatology·2014
Same author

Cystatin C is a sensitive marker for detecting a reduced glomerular filtration rate when assessing chronic kidney disease in patients with rheumatoid arthritis and secondary amyloidosis.

Scandinavian journal of rheumatology·2010
Same author

A prostacyclin agonist with thromboxane inhibitory activity for airway allergic inflammation in mice.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2009
Same author

Differences in lymphocyte profile between BAL fluid and human lung tissue from patients with interstitial lung disease.

British journal of biomedical science·2008

Area of Science:

  • Biomaterials Science
  • Nephrology
  • Medical Device Engineering

Background:

  • Developing effective ultrafiltration systems is crucial for managing acute renal failure.
  • Ensuring antithrombogenicity is a major challenge in extracorporeal circulation devices.
  • Conventional systems often require systemic anticoagulation, posing risks for certain patient populations.

Purpose of the Study:

  • To develop and evaluate a totally antithrombogenic continuous ultrafiltration system (ACUS).
  • To assess the performance, antithrombogenicity, and ultrafiltration stability of the ACUS.
  • To investigate the clinical applicability of ACUS in patients with acute renal failure.

Main Methods:

  • Interfacing a polyacrylonitrile (PAN)-polyethyleneoxide (PEO) membrane with heparin-bound components to create the ACUS.

Related Experiment Videos

  • In vitro assessment of heparin release and in vivo evaluation of partial thromboplastin time.
  • Animal experiments (unheparinized dog model) to determine extracorporeal circulation time and platelet compatibility.
  • Clinical application in two patients with acute renal failure.

    • Main Results:

    • The ACUS demonstrated persistent antithrombogenicity and stable ultrafiltration levels in animal studies.
    • Extracorporeal circulation time in unheparinized dogs was significantly longer with ACUS (458 min) compared to partially modified systems (<100 min).
    • ACUS showed good platelet compatibility with minimal platelet count fluctuation and no adherent platelets.
    • Clinical use in two patients achieved 44-hour hemofilter lifespan without systemic heparinization, maintaining stable ultrafiltration.

    Conclusions:

    • The developed ACUS exhibits excellent antithrombogenic properties and sustained performance.
    • The system is well-tolerated, showing good biocompatibility and minimal impact on coagulation parameters.
    • ACUS is a promising alternative for hemofiltration in patients with acute renal failure, particularly those with bleeding risks.